Olema Pharmaceuticals (OLMA) Payables (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Payables for 7 consecutive years, with $3.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables rose 2362.91% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $3.7 million (up 2362.91% YoY), while the FY2025 annual figure was $9.3 million, up 107.47% from the prior year.
• Payables slipped to $3.7 million in Q1 2026 per OLMA's latest filing, from $9.3 million in the prior quarter.
• Across five years, Payables topped out at $9.3 million in Q4 2025 and bottomed at $14000.0 in Q3 2022.
• Historically, Payables has averaged $2.6 million across 5 years, with a median of $2.2 million in 2023.
• Annual changes were most pronounced in 2023 — Payables soared 15664.29% — and 2025, when it tumbled 98.03%.
• Olema Pharmaceuticals' Payables stood at $374000.0 in 2022, then surged by 621.39% to $2.7 million in 2023, then surged by 65.31% to $4.5 million in 2024, then jumped by 107.47% to $9.3 million in 2025, then plunged by 59.81% to $3.7 million in 2026.
• Business Quant data shows OLMA's Payables at $3.7 million in Q1 2026, $9.3 million in Q4 2025, and $3.5 million in Q3 2025.